Reduced numbers of mature osteoblasts and osteocalcin in the blood, one of the surrogate markers of osteoblast function, were reported in both AML patients and the MLL-AF9 mouse aggressive AML model, resulting in reduced healthy hematopoiesis (94, 95). This evidence concerns the gene KMT2A and acute myeloid leukemia.